Mer­ck, Am­gen back a $30M play for Ri­bometrix — one of the up­starts mak­ing its mark in drug­ging RNA

The idea that you can drug RNA has at­tract­ed a va­ri­ety of biotech star­tups in­ter­est­ed in pi­o­neer­ing a new tech­nol­o­gy. And one of those biotechs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA